| Dateline Resources Limited (DTR) ORDINARY FULLY PAID |
Materials |
$345 |
GRES Appointment Strengthens Colosseum Feasibility Study
|
21 Aug 2025 8:59AM |
$0.210 |
$0.086 |
fallen by
59.05%
|
|
| IDT Australia Limited (IDT) ORDINARY FULLY PAID |
Health Care |
$20 |
FY25 Full Year Profit Results
|
21 Aug 2025 8:59AM |
$0.069 |
$0.047 |
fallen by
31.88%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$27 |
Appendix 4G & Corporate Governance Statement
|
21 Aug 2025 8:59AM |
$0.540 |
$0.580 |
risen by
7.41%
|
|
| Centuria Industrial REIT (CIP) ORDINARY UNITS FULLY PAID |
Real Estate |
$1,929 |
Update - Notification of buy-back - CIP
|
21 Aug 2025 8:58AM |
$3.390 |
$3.090 |
fallen by
8.85%
|
|
| Qube Holdings Limited (QUB) ORDINARY FULLY PAID |
Industrials |
$9,117 |
Investor Presentation - 2025 Full Year Results
|
21 Aug 2025 8:58AM |
$4.500 |
$5.110 |
risen by
13.56%
|
|
QUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 27.4% to $4,461.2 million.
- Logistics & Infrastructure revenue grew by 57.4%.
- Ports & Bulk division revenue increased by 3.5%.
- EBITDA margin reported at 14.7%.
- EBITA margin slightly decreased despite revenue growth.
- Lease accounting and discontinued operations adjusted in results.
- Significant capital expenditure in acquisitions and maintenance.
- Net finance costs were reduced considerably.
- Improvement in net profit attributable to Qube.
- Focus on safety improvements and strategic investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qube Holdings Limited (QUB) ORDINARY FULLY PAID |
Industrials |
$9,117 |
Investor Presentation - 2025 Full Year Results
|
21 Aug 2025 8:58AM |
$4.500 |
$5.110 |
risen by
13.56%
|
|
QUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 27.3% to $4,461.4 million.
- EBITDA grew by 15.4% to $616.2 million.
- Net profit attributable to Qube rose by 5.5% to $272.1 million.
- Significant acquisitions included Colemans and MIRRAT.
- Capital expenditure focused on property and mobile fleet assets.
- Net gain of $89.7 million from Minto property disposal.
- Impairment of $127.6 million due to MITCo investment.
- Affected by leasing standards and discontinued operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
- |
Landmark EEG Biomarker Agreement for Precision Psychiatry
|
21 Aug 2025 8:58AM |
$0.033 |
$0.034 |
risen by
3.03%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Tryptamine Therapeutics Limited announced a collaboration with MindBio Therapeutics Corp.
- The agreement grants TYP access to MindBio’s EEG Brain Mapping AI Biomarker Platform.
- This technology helps predict patient responses to psychedelic medicines using EEG data and AI analysis.
- TYP will use the biomarker platform in its precision psychiatry clinical programs.
- The partnership aims to enable more personalized and effective mental health treatments.
- Integrating AI-powered biomarkers is expected to optimize clinical trial success and accelerate therapy delivery.
- The collaboration signifies TYP’s strategic focus on innovation and advanced neurotechnology in mental healthcare.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Downer EDI Limited (DOW) ORDINARY FULLY PAID |
Industrials |
$5,061 |
FY25 Results Presentation
|
21 Aug 2025 8:57AM |
$6.930 |
$7.680 |
risen by
10.82%
|
|
DOW - Price-sensitive ASX Announcement
Full Release
Key Points
- EBIT increased by 26.7% to $453.2 million.
- Net profit after tax rose by 36.5% to $264.7 million.
- Total revenue decreased by 9% to $10,885.7 million.
- Achieved $213 million in cost reductions, exceeding targets.
- Significant divestments included Keolis Downer and non-core businesses.
- Shift towards a services-led model, exiting mining and construction.
- Focus on operational improvements and risk management.
- Transformation program aimed at sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Downer EDI Limited (DOW) ORDINARY FULLY PAID |
Industrials |
$5,061 |
FY25 Results Presentation
|
21 Aug 2025 8:57AM |
$6.930 |
$7.680 |
risen by
10.82%
|
|
DOW - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying EBITA increased by 24.5% to $474.2 million.
- Strong cash conversion rate of 98% was maintained.
- Substantial statutory EBIT and NPAT growth.
- Successful implementation of a $213 million cost-out program.
- Strategic exits from low-margin operations and divestments were executed.
- The balance sheet was strengthened, supporting future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medical Developments International Limited (MVP) ORDINARY FULLY PAID |
Health Care |
$54 |
MVP Announces FY25 Full Year Results
|
21 Aug 2025 8:57AM |
$0.635 |
$0.480 |
fallen by
24.41%
|
|
MVP - Price-sensitive ASX Announcement
Full Release
Key Points
- Medical Developments International Limited (MVP) announced its full-year results for FY25.
- Revenue for the year was reported at $22.9 million, with a net loss after tax of $7.5 million.
- The company experienced growth in its Penthrox business, with international sales increasing due to new market entries and expansion in existing markets.
- Domestic sales were impacted by ongoing challenges in the Australian market, including regulatory delays and competitive pressures.
- MVP invested in research and development, regulatory submissions, and clinical trials to support pipeline products and expand Penthrox indications.
- Operating expenses increased due to higher investment in commercialization activities, international expansion, and regulatory costs.
- The company highlighted progress in its partnership strategies, including collaborations with major pharmaceutical companies for global distribution.
- Cash reserves were managed through a combination of capital raising and operational cost controls.
- The outlook for FY26 includes continued focus on international market expansion, product innovation, and improving operational efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$34 |
Appendix 4G & Corporate Governance Statement
|
21 Aug 2025 8:57AM |
$0.340 |
$0.460 |
risen by
35.29%
|
|
| Medical Developments International Limited (MVP) ORDINARY FULLY PAID |
Health Care |
$54 |
FY25 Full Year Results
|
21 Aug 2025 8:57AM |
$0.635 |
$0.480 |
fallen by
24.41%
|
|
MVP - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant revenue growth and improved financial performance in FY25.
- Focused strategy on core business areas, especially pain management and Penthrox.
- Reduction of net loss and improvement in operating margins.
- Disciplined cost management and supply chain optimization.
- Continued investment in regulatory submissions and international expansion.
- Management reiterated a clear vision for sustainable long-term shareholder value.
- Emphasis on innovation and operational excellence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Storage REIT (NSR) ORDINARY FULLY PAID |
Real Estate |
- |
NSR 2025 Results Presentation
|
21 Aug 2025 8:56AM |
$2.440 |
$2.790 |
risen by
14.34%
|
|
| Sonic Healthcare Limited (SHL) ORDINARY FULLY PAID |
Health Care |
$11,022 |
Preliminary Final Report
|
21 Aug 2025 8:56AM |
$28.740 |
$22.300 |
fallen by
22.41%
|
|
SHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Sonic Healthcare Limited reported a revenue of A$9,645,448,000 for the year ended 30 June 2025, showing a growth of 7.6%.
- Profit after tax attributable to members was A$513,597,000, a slight increase of 0.5% from the previous year.
- The effective tax rate for the year was 27.6%, slightly higher than the previous guidance due to jurisdictional variances.
- Cash generated from operations was significantly higher, owing to a 48% reduction in income taxes paid, compared to previous years.
- Dividends were declared with a final dividend of 63 cents per share and an interim dividend of 44 cents per share.
- Sonic Healthcare completed the acquisition of Laboratory Group Dr. Kramer & Colleagues on 1 July 2025.
- The company experienced operational disruptions in the USA due to a cyber event impacting billing and debt collection.
- Guidance for FY2026 includes expected EBITDA in the range of A$1.87 to A$1.95 billion.
- Net tangible asset backing per ordinary security was reported at $(2.69).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sonic Healthcare Limited (SHL) ORDINARY FULLY PAID |
Health Care |
$11,022 |
Preliminary Final Report
|
21 Aug 2025 8:56AM |
$28.740 |
$22.300 |
fallen by
22.41%
|
|
SHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 7.6% to $9,645,448,000.
- Profit after tax attributable to members was $513,597,000.
- Total equity at the end of the financial year was $8,473,216,000.
- Final dividend declared at 63 cents per share.
- Major revenue from laboratory services.
- Consistent shareholder returns policy with suspended Dividend Reinvestment Plan.
- Emphasized strategic growth through acquisitions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gateway Mining Limited (GML) ORDINARY FULLY PAID |
Materials |
$184 |
Trading Halt
|
21 Aug 2025 8:55AM |
$0.028 |
$0.079 |
risen by
182.14%
|
|
GML - Price-sensitive ASX Announcement
Full Release
Key Points
- Gateway Mining Limited (GML) has requested a trading halt from the ASX.
- The trading halt is sought pending an announcement about a proposed capital raising.
- The trading halt will be effective from 29 May 2023.
- The halt will last until the earlier of the announcement being made or market open on 31 May 2023.
- The purpose of the halt is to ensure a fair and informed market.
- The company's request is in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medical Developments International Limited (MVP) ORDINARY FULLY PAID |
Health Care |
$54 |
FY25 Full Year Results Investor Presentation
|
21 Aug 2025 8:55AM |
$0.635 |
$0.480 |
fallen by
24.41%
|
|
MVP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 full year financial results show strong revenue growth and improved EBITDA.
- Pain Management segment, led by Penthrox, remains the primary growth driver.
- International market expansion, especially in Europe and Asia-Pacific, is progressing well.
- Investments continue in regulatory approvals, research, and new product development.
- Strategic partnerships and ongoing clinical trials support long-term growth.
- Supply chain and regulatory challenges remain but are being actively managed.
- Board commits to disciplined capital management and reinvestment in key business areas.
- Positive outlook for revenue growth and operational improvements in the coming year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,332 |
Update - Notification of buy-back - WHC
|
21 Aug 2025 8:54AM |
$6.430 |
$7.700 |
risen by
19.75%
|
|
| Downer EDI Limited (DOW) ORDINARY FULLY PAID |
Industrials |
$5,061 |
FY25 Results Media Release
|
21 Aug 2025 8:54AM |
$6.930 |
$7.680 |
risen by
10.82%
|
|
DOW - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT of $149.1 million, an 81.6% increase.
- Underlying NPATA growth of 33% to $279.4 million.
- EBITA margin of 4.4%, highest in over 10 years.
- Net debt to EBITDA improved to 0.9x.
- Cash conversion rate of 97.9%.
- Final dividend of 14.1 cps, fully franked.
- Announcement of $230 million share buy-back.
- Strategic divestments and focus on core growth.
- Plans for digitization and AI investments in FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Downer EDI Limited (DOW) ORDINARY FULLY PAID |
Industrials |
$5,061 |
FY25 Results Media Release
|
21 Aug 2025 8:54AM |
$6.930 |
$7.680 |
risen by
10.82%
|
|
DOW - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT of $149.1 million, up 81.6% from the prior year
- Underlying NPATA of $279.4 million, a 33% increase
- Improved EBITA margin to 4.4%
- Declared a fully franked final dividend of 14.1 cents per share
- Announced $230 million share buyback
- Net debt to EBITDA improved to 0.9x
- Completed divestments for portfolio simplification
- Focus on core markets and growth opportunities
- Entering FY26 with stable market conditions
- Plans for modernisation and targeting sustainable growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Infinity Mining Limited (IMI) ORDINARY FULLY PAID |
Materials |
$4 |
IRGS Gold Targets defined at Tanjil Bren & Walhalla South
|
21 Aug 2025 8:54AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
IMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Infinity Mining Limited (IMI) has advanced exploration at Tanjil Bren and Walhalla South in the Central Victorian Goldfields, confirming the presence of Intrusion-Related Gold System (IRGS) targets.
- A comprehensive review and analysis of recent and historical exploration data has led to the identification of several new gold targets with IRGS affinities.
- The Tanjil Bren project area contains multiple gold prospects, with geological similarities to the Fosterville and Costerfield gold deposits.
- Field mapping, sampling, and geochemical surveys have delineated areas of strong gold anomalism associated with intrusive-related alteration zones.
- The company has prioritized drill targets based on geochemical, geophysical, and structural criteria for further testing.
- Walhalla South has also shown significant potential with multiple gold prospects identified, supported by historical mining records and recent sampling results.
- IMI plans to undertake further fieldwork, including geophysics and drilling, to test the newly defined IRGS targets and refine their exploration models.
- The company highlights the potential for large-scale, high-grade gold mineralization in both project areas due to their geological setting and exploration results.
- Community engagement and compliance with regulatory frameworks are stated as ongoing priorities for the exploration programs.
- IMI reaffirms its commitment to systematic exploration to unlock value from these prospective gold projects in Victoria.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$43 |
Dividend/Distribution - NSC
|
21 Aug 2025 8:54AM |
$0.340 |
$0.325 |
fallen by
4.41%
|
|
| Charter Hall Group (CHC) STAPLED SECURITIES US PROHIBITED |
Real Estate |
$11,144 |
Appendix 4G
|
21 Aug 2025 8:53AM |
$22.820 |
$23.560 |
risen by
3.24%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$27 |
Dividend/Distribution - NAC
|
21 Aug 2025 8:53AM |
$0.540 |
$0.580 |
risen by
7.41%
|
|
| Charter Hall Group (CHC) STAPLED SECURITIES US PROHIBITED |
Real Estate |
$11,144 |
Corporate Governance Statement
|
21 Aug 2025 8:53AM |
$22.820 |
$23.560 |
risen by
3.24%
|
|
Call 1300 880 160
Start a chat
Schedule a call
